Myosana Therapeutics

Building New Gene Therapies for Muscle and Heart Diseases

https://wefunder.com/myosana.therapeutics

Total raised on Wefunder: 595311

Total investors: 67

Quick facts

• Developing a gene therapy treatment for Duchenne muscular dystrophy (DMD).
• Designed to deliver full-length dystrophin to skeletal and cardiac muscle.
• Uses proprietary GLUT4-targeting antibodies to deliver DNA to muscle cells efficiently.
• Non-viral design allows repeat dosing, unlike most viral gene therapies.
• Investment from Parent Project Muscular Dystrophy, CureDuchenne Ventures, angel investor.
• Preclinical studies show significant dystrophin expression in DMD animal models.
• DMD treatment market projected to reach about $10B by 2030.
• A founding team with extensive experience in neuromuscular disease research and drug development.

Team profiles

• Nicholas Whitehead
• Stan Froehner
• Agrippina Agrippina

Featured investor profiles

• John Ballantyne
• Parent Project Muscular Dystrophy
• Muscular Dystrophy Association
• Cure Duchenne